Graffinity secures Lilly deal

July 26, 2002 — Graffinity Pharmaceuticals AG, a Heidelberg, Germany, developer of chemical genomics technology, has secured an agreement with Eli Lilly and Co. to identify small molecule compounds against a selection of Lilly’s therapeutic targets.

Graffinity’s drug discovery platform includes chemical microarrays. Financial terms of the deal were not disclosed.


Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.